08.20.14 -- Pfizer's Dr. Firelli Alonso-Caplen Discusses Outsourcing Challenges And The Future Of Single Use
Life Science Leader and BayBio bring you interactive panels on the challenges to managing outsourcing relationships. Panelists include Andy Skibo (RVP, AstraZeneca; EVP, MedImmune), David Lowndes (SVP, Shire), Bob Kanuga (VP, Merck), Junning Lee (SVP, Theravance Biopharma), Terry Novak (COO, Pernix Therapeutics), and others. Learn more.
Guest Column: A Powerful Method To Develop Highly Concentrated Protein Formulations By Michelle Amaral, Ph.D., Science Writer, Soluble Therapeutics
Proteins perform an array of functions in living organisms, from structural scaffolds and signaling molecules to catalysts and cell-surface receptors. Structural perturbations and aberrant protein production are associated with many disease states, making these macromolecules potential candidates for pharmaceuticals. This strategy became a reality following the advent of recombinant DNA technologies, which allowed proteins to be produced on a large scale. Issues related to protein solubility can limit this approach however, and drastically reduce the number of possible therapeutics that can be delivered to patients. “Solutions” to this problem are highly desirable.
White Paper: Using Dry Ice When Shipping Air Freight By Mark Mohr, CSafe Global
Healthcare product manufacturers, transportation providers, and distributors all have a moral, and in most cases, a regulatory responsibility to help ensure product arrives to the end user intact. Protection of product efficacy demands use of the latest reliable technologies available. People’s lives truly depend on it.
Discover how to increase the production and quality of your cell lines more efficiently by attending IBC's 10th Annual Cell Line Development and Engineering meeting, taking place September 8 to 10, 2014, in Berkeley, CA. Save 20 percent off the standard rate with priority code B14189BIO. View the full program and register online today.
ASI’s single-use systems are designed to be built around the customer’s process, not the other way around. This customer process-first distinction proves that increased cost control, as well as the ability to meet a compressed or aggressive schedule, is a high-value benefit that simply cannot be found anywhere else.
To assist our audience with getting the specific scientific and business information they need to do their jobs better, we are narrowing our editorial coverage of this site to the bio manufacturing industry. As a result, this September, Bioresearch Online will become BioProcess Online.